ClinicalTrials.gg
CompletedNCT06266663Updated Nov 4, 2026

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

An observational study in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Montefiore Medical Center. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Montefiore Medical Center · Observational

How we know

Updated Nov 4, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
366
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
45th of 132
366 · median 134
Started
2024
with 20 others
Observational
133 of 463
39 open now
Registered
397th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 45th largest by enrollment of the 132 observational ones that give a count, is one of 21 that started in 2024, is one of 133 observational ones, and was the 397th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

Optimizing health related-quality of life (HRQoL) for patients with inflammatory bowel disease (IBD), who often experience a relapsing disease course, is an essential component of care. Improving IBD disease control is linked to increased health-related quality of life. Even as many effective pharmacotherapies to promote disease control are available, evidence suggests that Hispanic and Non-Hispanic Black IBD patients may not receive full benefit from these therapies compared to their Non-Hispanic White counterparts. Underlying mechanisms that contribute to observed disparities in the use of IBD medical therapies are likely multifactorial. Adequate access to treatment has been implicated. Hispanic and Non-Hispanic Black IBD patients are more likely to be Medicaid-insured, and Medicaid insurance has been associated with increased emergency room visits, a proxy for sub-optimal IBD control. Medication adherence has also been proposed as a potential mediating factor. IBD therapies can be time-consuming and costly, which can pose a challenge in achieving medication adherence. While previous studies suggest Black IBD patients have lower medication adherence than Non-Hispanic White patients, it is unclear the extent to which social factors contribute to this observation. The purpose of this study is to evaluate the association between social determinants of health, medication adherence, and HRQoL among Hispanic and Non-Hispanic Black IBD patients. Understanding potentially modifiable psychosocial factors that contribute to medication adherence and HRQoL will provide targets for later intervention towards the goal of health equity.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients age 18 years or older with IBD who meet the above inclusion/exclusion criteria will be eligible to participate in the study. Participants will be grouped by race and ethnicity (Hispanic, Non-Hispanic Black, or Non-Hispanic White). Participants who identify as Hispanic will be further grouped by preferred language (English or Spanish). Participants will also be grouped into either public (e.g. Medicaid, Medicare) or private insurance. The study team plans to recruit 25 participants per cell: race and ethnicity (4), study site (2), insurance (2). Target recruitment is 200 participants per site for a total of 400 participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of Crohn's disease, ulcerative colitis, or indeterminate colitis for at least 3 months investigator confirmed on the basis of supportive clinical data such as colonoscopy, pathology and/or radiology
  • age 18 years or older
  • ability to provide in English or Spanish
  • basic computer proficiency (i.e., to complete online survey)

Exclusion criteria

Exclusion Criteria:

  • race and ethnicity self-identified as other than Hispanic, Non-Hispanic Black, or Non-Hispanic White
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
366 participants (actual)
Patient registry
No

Interventions

  • OtherSurvey

    A cross-sectional survey of 400 IBD patients who will be actively recruited from the gastroenterology (GI) specialty clinics at Einstein-Montefiore Medical Center and Icahn School of Medicine at Mount Sinai Hospital. The survey will consist of validated screening measures on social domains known to affect health outcomes as well as measures of medication adherence and HRQoL.

06

What researchers measure

Primary outcomes

  1. IBD medication adherence

    The outcome of IBD medication adherence will be categorized by the adapted Hill Bone Medication Adherence Scale (HB-MAS). This part of the questionnaire consists of eight items used to assess patients' self-reported IBD oral medication adherence. Participant responses are scored on a scale from 1-4 (1 = All of the time; 2 = Most of the time; 3 = Some of the time; 4 = None of the time). Lower overall scores are associated with better medication adherence

    Time frame: Single 20 minute survey response, upon participant enrollment

  2. Health-related quality of life (HRQoL)

    HRQoL will be categorized based on responses to the NIH Patient Reported Outcomes Measurement Information System-29 (PROMIS-29). PROMIS-29 assesses each of 7 domains (Depression, Anxiety, Physical function, Pain interference, Fatigue, Sleep disturbance, Ability to participate in social roles and activities) using 4 questions with an additional Pain Intensity question. Participants' responses are scored from 1-5 (with the exception of the Pain Intensity Question which is scored from 0-10). The sum of each of the 7 PROMIS domains results in a raw score (from 4-20). There is no total score. Each axis forms its own score. PROMIS assessments use an Item Response Theory (IRT) based score called "Expected A Posteriori" (EAP) scores, which are then transformed to a final T-score metric. As such, scores are mapped so that the values follow a normal distribution with a population mean T-score of 50 and a standard deviation of 10

    Time frame: Single 20 minute survey response, upon participant enrollment

07

Study locations

2 sites
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Montefiore Hutchinson Campus
    The Bronx, New York 10461, United States
08

References and documents

Publications

  • Szigethy EM, Allen JI, Reiss M, Cohen W, Perera LP, Brillstein L, Cross RK, Schwartz DA, Kosinski LR, Colton JB, LaRusso E, Atreja A, Regueiro MD. White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017 Jul;15(7):986-997. doi: 10.1016/j.cgh.2017.02.037. Epub 2017 Mar 12. PubMed 28300693 ↗
  • Kappelman MD, Long MD, Martin C, DeWalt DA, Kinneer PM, Chen W, Lewis JD, Sandler RS. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1315-23.e2. doi: 10.1016/j.cgh.2013.10.019. Epub 2013 Oct 29. PubMed 24183956 ↗
  • Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. 2010 Oct;105(10):2202-8. doi: 10.1038/ajg.2010.202. Epub 2010 May 18. PubMed 20485281 ↗
  • Damas OM, Jahann DA, Reznik R, McCauley JL, Tamariz L, Deshpande AR, Abreu MT, Sussman DA. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol. 2013 Feb;108(2):231-9. doi: 10.1038/ajg.2012.393. Epub 2012 Dec 18. PubMed 23247580 ↗
  • Barnes EL, Loftus EV Jr, Kappelman MD. Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology. 2021 Feb;160(3):677-689. doi: 10.1053/j.gastro.2020.08.064. Epub 2020 Oct 21. PubMed 33098884 ↗
  • Nguyen GC, Sam J, Murthy SK, Kaplan GG, Tinmouth JM, LaVeist TA. Hospitalizations for inflammatory bowel disease: profile of the uninsured in the United States. Inflamm Bowel Dis. 2009 May;15(5):726-33. doi: 10.1002/ibd.20825. PubMed 19067416 ↗
  • Nguyen GC, LaVeist TA, Harris ML, Datta LW, Bayless TM, Brant SR. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009 Aug;15(8):1233-9. doi: 10.1002/ibd.20883. PubMed 19177509 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2024 to primary completion in Aug 2026, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 20, 2024
StartActual
Apr 26, 2024
Primary completionActual
Aug 26, 2026was Sep 2026
CompletionActual
Aug 26, 2026was Sep 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Primary completion
Sep 30, 2026→Aug 26, 2026 (actual)
Nov 4, 2026
Study completion
Sep 30, 2026→Aug 26, 2026 (actual)
Nov 4, 2026
Enrollment
400 (estimated)→366 (actual)
Nov 4, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • Editedclinical diagnosis of Crohn's disease, ulcerative colitis, or indeterminate colitis ≥for at least 3 months investigator confirmed on the basis of supportive clinical data such as colonoscopy, pathology and/or radiology
  • Editedbasic computer proficiency (i.e., to complete online survey)
Nov 4, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionHealth-related quality of life (HRQoL): how it is measured was reworded
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2026→Aug 26, 2026 (now actual)
    Study completion Sep 30, 2026→Aug 26, 2026 (now actual)
    Enrollment 400 (estimated)→366 (actual)
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • Editedclinical diagnosis of Crohn's disease, ulcerative colitis, or indeterminate colitis ≥for at least 3 months investigator confirmed on the basis of supportive clinical data such as colonoscopy, pathology and/or radiology
    • Editedbasic computer proficiency (i.e., to complete online survey)
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionHealth-related quality of life (HRQoL): how it is measured was reworded
    + 6 other changes: verification date, conditions, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06266663
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Apr 26, 2024
Primary completion
Aug 26, 2026
Completion
Aug 26, 2026
Last update
Nov 4, 2026

Study contacts

Ruby Greywoode, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion